Cardiovascular Diseases Clinical Trial
Official title:
Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
This safety pilot study evaluates the effect of hydroxychloroquine on preventing recurrent cardiovascular events among myocardial infarction patients. Half of the participants will receive hydroxychloroquine, whereas the other half will receive placebo during six months.
Anti-rheumatic medications decrease cardiovascular mortality in rheumatoid arthritis
patients, based mainly on their anti-inflammatory effect. No studies have addressed their
effect on preventing recurrent cardiovascular events among non-rheumatic patients.
In the pilot phase 200 myocardial infarction patients will be recruited during their index
visit to the study hospitals. Patients will be randomized after initial coronary angiography
to receive either hydroxychloroquine 300 mg a day or placebo during six months. Patients will
be followed up until 12 months at four visits. Visit one is at doctor´s office at 3 to 5
weeks from the day of recruitment. Visit two is at study nurse´s office at 5.5 to 6 months.
Visit three is a phone interview by the study nurse at 8.5 to 9.5 months. Visit four at 11.5
to 12.5 months is at doctor´s office.
This study evaluates the safety of hydroxychloroquine in the setting of myocardial
infarction, and whether hydroxychloroquine treatment could reduce the incidence of recurrent
cardiovascular events among myocardial infarction patients. Furthermore, the effect of
hydroxychloroquine on cardiovascular risk factors and systemic inflammation parameters will
be studied. In a subgroup of 40 patients, the effect of hydroxychloroquine on aortic
inflammation will be assessed by PET/CT scan.
If this safety pilot study with 200 patients proves successful (i.e. no major complications),
2500 patients will be recruited in additional centers in Finland and the Nordic Countries.
Orion Pharma provides the active hydroxychloroquine tablet (Oxiklorin) but provides no other
assistance or funding for the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|